Lenarz T
Scand Audiol Suppl. 1986;26:49-51.
The efficacy of lidocaine and tocainide in the rational treatment of tinnitus aurium was evaluated in a double-blind randomized cross over study against saline as placebo. Forty patients with severe long lasting (more than six months) tinnitus and sensorineural hearing loss were included in the study. In 24 patients treated with lidocaine (loading dose: 3 mg/kg body weight in 10 min; maintenance dose: 1 mg/kg in 20 min), in 19 patients treated with tocainide infusion (750 mg in 30 min), and 10 patients treated with tocainide orally (400 to 2,400 mg per day), tinnitus intensity was reduced by more than 50%, compared with placebo (designated as a positive result). In some patients, ABRs showed prolongation of interpeak latencies (IPLs) indicating a retrochlear site of drug action. This hypothesis is supported by our own animal experiments with lidocaine in rabbits. IPLs showed a dose dependent reversible prolongation without hearing loss.
在一项双盲随机交叉研究中，以生理盐水作为安慰剂，评估利多卡因和妥卡尼在耳鸣合理治疗中的疗效。该研究纳入了40例患有严重长期（超过6个月）耳鸣且伴有感音神经性听力损失的患者。24例接受利多卡因治疗的患者（负荷剂量：10分钟内3mg/kg体重；维持剂量：20分钟内1mg/kg），19例接受妥卡尼静脉输注治疗的患者（30分钟内750mg），以及10例口服妥卡尼治疗的患者（每天400至2400mg），与安慰剂相比，耳鸣强度降低超过50%（被视为阳性结果）。在一些患者中，听性脑干反应（ABR）显示峰间期（IPL）延长，表明药物作用部位在蜗后。我们自己在兔子身上进行的利多卡因动物实验支持了这一假设。IPL显示出剂量依赖性可逆延长且无听力损失。
